Prostate cancer: No benefit of combining custirsen with cabazitaxel

scientific article published on 8 November 2017

Prostate cancer: No benefit of combining custirsen with cabazitaxel is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/NRUROL.2017.193
P698PubMed publication ID29116255

P50authorClemens ThomaQ67192756
P2860cites workCustirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, internationQ47651210
P433issue12
P407language of work or nameEnglishQ1860
P304page(s)700
P577publication date2017-11-08
P1433published inNature Reviews UrologyQ2079265
P1476titleProstate cancer: No benefit of combining custirsen with cabazitaxel
P478volume14